Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

Bibliographic Details
Title:	Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
Authors:	Camille Tessier, Thomas Allard, Jean-Samuel Boudreault, Rayan Kaedbey, Vincent Éthier, Fléchère Fortin, Michel Pavic
Source:	Current Oncology, Vol 28, Iss 3, Pp 2029-2039 (2021)
Publisher Information:	MDPI AG, 2021.
Publication Year:	2021
Collection:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms:	smoldering multiple myeloma, multiple myeloma, risk stratification model, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details:	Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free light chain ratio (FLCr) > 20 and serum M protein > 20 g/L. The goal of our study was to test this “20/20/20” model in our population and to determine if similar results could be obtained in another cohort of SMM patients. Method—we conducted a retrospective, single center study with 89 patients diagnosed with SMM between January 2008 and December 2019. Results—all three tested biomarkers were associated with an increased risk of progression: BMPC percentage ≥ 20% (hazard ratio [HR]: 4.28 [95%C.I., 1.90–9.61]; p < 0.001), serum M protein ≥ 20 g/L (HR: 4.20 [95%C.I., 1.90–15.53]; p = 0.032) and FLCr ≥ 20 (HR: 3.25 [95%C.I., 1.09–9.71]; p = 0.035). The estimated median time to progression (TTP) was not reached for the low and intermediate risk groups and was 29.1 months (95%C.I., 3.9–54.4) in the high-risk group (p = 0.006). Conclusions—the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1718-7729 1198-0052
Relation:	https://www.mdpi.com/1718-7729/28/3/188; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729
DOI:	10.3390/curroncol28030188
Access URL:	https://doaj.org/article/697c3a00e7d6409988aa1b91222f3189
Accession Number:	edsdoj.697c3a00e7d6409988aa1b91222f3189
Database:	Directory of Open Access Journals

More Details
ISSN:	17187729 11980052
DOI:	10.3390/curroncol28030188
Published in:	Current Oncology
Language:	English